Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Identifieur interne : 003C28 ( Main/Exploration ); précédent : 003C27; suivant : 003C29Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Auteurs : Josep Tabernero [Espagne] ; Eric Van Cutsem [Belgique] ; Radek Lakom [République tchèque] ; Jana Prausová [République tchèque] ; Paul Ruff [Afrique du Sud] ; Guy A. Van Hazel [Australie] ; Vladimir M. Moiseyenko [Russie] ; David R. Ferry [Royaume-Uni] ; Joseph J. Mckendrick [Australie] ; Karen Soussan-Lazard [France] ; Soazig Chevalier [France] ; Carmen J. Allegra [États-Unis]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Bévacizumab, Calendrier d'administration des médicaments, Camptothécine (administration et posologie), Camptothécine (analogues et dérivés), Camptothécine (effets indésirables), Diarrhée (), Estimation de Kaplan-Meier, Fatigue (), Fluorouracil (administration et posologie), Fluorouracil (effets indésirables), Humains, Leucovorine (administration et posologie), Leucovorine (effets indésirables), Métastase tumorale, Méthode en double aveugle, Neutropénie (), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Protéines de fusion recombinantes (administration et posologie), Protéines de fusion recombinantes (effets indésirables), Récepteurs aux facteurs de croissance endothéliale vasculaire (administration et posologie), Récepteurs aux facteurs de croissance endothéliale vasculaire (effets indésirables), Résultat thérapeutique, Sujet âgé, Tumeurs colorectales (anatomopathologie), Tumeurs colorectales (traitement médicamenteux), Études prospectives.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Camptothécine, Fluorouracil, Leucovorine, Protéines de fusion recombinantes, Récepteurs aux facteurs de croissance endothéliale vasculaire.
- analogues et dérivés : Camptothécine.
- anatomopathologie : Tumeurs colorectales.
- effets indésirables : Camptothécine, Fluorouracil, Leucovorine, Protocoles de polychimiothérapie antinéoplasique, Protéines de fusion recombinantes, Récepteurs aux facteurs de croissance endothéliale vasculaire.
- traitement médicamenteux : Tumeurs colorectales.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte d'âge moyen, Bévacizumab, Calendrier d'administration des médicaments, Diarrhée, Estimation de Kaplan-Meier, Fatigue, Humains, Métastase tumorale, Méthode en double aveugle, Neutropénie, Résultat thérapeutique, Sujet âgé, Études prospectives.
English descriptors
- KwdEn :
- Aged, Antibodies, Monoclonal, Humanized (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bevacizumab, Camptothecin (administration & dosage), Camptothecin (adverse effects), Camptothecin (analogs & derivatives), Colorectal Neoplasms (drug therapy), Colorectal Neoplasms (pathology), Diarrhea (chemically induced), Double-Blind Method, Drug Administration Schedule, Fatigue (chemically induced), Fluorouracil (administration & dosage), Fluorouracil (adverse effects), Humans, Kaplan-Meier Estimate, Leucovorin (administration & dosage), Leucovorin (adverse effects), Middle Aged, Neoplasm Metastasis, Neutropenia (chemically induced), Prospective Studies, Receptors, Vascular Endothelial Growth Factor (administration & dosage), Receptors, Vascular Endothelial Growth Factor (adverse effects), Recombinant Fusion Proteins (administration & dosage), Recombinant Fusion Proteins (adverse effects), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Camptothecin, Fluorouracil, Leucovorin, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Fluorouracil, Leucovorin, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- chemical , analogs & derivatives : Camptothecin.
- chemically induced : Diarrhea, Fatigue, Neutropenia.
- drug therapy : Colorectal Neoplasms.
- pathology : Colorectal Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Bevacizumab, Double-Blind Method, Drug Administration Schedule, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Metastasis, Prospective Studies, Treatment Outcome.
Abstract
The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the present analysis, outcomes were evaluated in prespecified subgroups to assess the consistency of the treatment effect.
DOI: 10.1016/j.ejca.2013.09.013
PubMed: 24140268
Affiliations:
- Afrique du Sud, Australie, Belgique, Espagne, France, Royaume-Uni, Russie, République tchèque, États-Unis
- Bohême centrale, Catalogne, Moravie
- Barcelone, Brno, Prague
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003A09
- to stream PubMed, to step Curation: 003885
- to stream PubMed, to step Checkpoint: 003885
- to stream Ncbi, to step Merge: 001527
- to stream Ncbi, to step Curation: 001527
- to stream Ncbi, to step Checkpoint: 001527
- to stream Main, to step Merge: 003C78
- to stream Main, to step Curation: 003C28
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.</title><author><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name><affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: jtabernero@vhio.net.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals Leuven and KU Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospitals Leuven and KU Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Lakom, Radek" sort="Lakom, Radek" uniqKey="Lakom R" first="Radek" last="Lakom">Radek Lakom</name><affiliation wicri:level="3"><nlm:affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Masaryk Memorial Cancer Institute, Brno</wicri:regionArea><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation></author><author><name sortKey="Prausova, Jana" sort="Prausova, Jana" uniqKey="Prausova J" first="Jana" last="Prausová">Jana Prausová</name><affiliation wicri:level="3"><nlm:affiliation>Fakultni nemocnice v Motole, Praha, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Fakultni nemocnice v Motole, Praha</wicri:regionArea><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation></author><author><name sortKey="Ruff, Paul" sort="Ruff, Paul" uniqKey="Ruff P" first="Paul" last="Ruff">Paul Ruff</name><affiliation wicri:level="1"><nlm:affiliation>University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>University of Witwatersrand Faculty of Health Sciences, Johannesburg</wicri:regionArea><wicri:noRegion>Johannesburg</wicri:noRegion></affiliation></author><author><name sortKey="Van Hazel, Guy A" sort="Van Hazel, Guy A" uniqKey="Van Hazel G" first="Guy A" last="Van Hazel">Guy A. Van Hazel</name><affiliation wicri:level="1"><nlm:affiliation>University of Western Australia, Western Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Western Australia, Western Australia</wicri:regionArea><wicri:noRegion>Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Moiseyenko, Vladimir M" sort="Moiseyenko, Vladimir M" uniqKey="Moiseyenko V" first="Vladimir M" last="Moiseyenko">Vladimir M. Moiseyenko</name><affiliation wicri:level="1"><nlm:affiliation>Oncology Research Institute Na.NN.Petrov, St-Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Oncology Research Institute Na.NN.Petrov, St-Petersburg</wicri:regionArea><wicri:noRegion>St-Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Ferry, David R" sort="Ferry, David R" uniqKey="Ferry D" first="David R" last="Ferry">David R. Ferry</name><affiliation wicri:level="1"><nlm:affiliation>Russells Hall Hospital, Dudley, West Midlands, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Russells Hall Hospital, Dudley, West Midlands</wicri:regionArea><wicri:noRegion>West Midlands</wicri:noRegion></affiliation></author><author><name sortKey="Mckendrick, Joseph J" sort="Mckendrick, Joseph J" uniqKey="Mckendrick J" first="Joseph J" last="Mckendrick">Joseph J. Mckendrick</name><affiliation wicri:level="1"><nlm:affiliation>Monash University, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash University, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Soussan Lazard, Karen" sort="Soussan Lazard, Karen" uniqKey="Soussan Lazard K" first="Karen" last="Soussan-Lazard">Karen Soussan-Lazard</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi, Vitry-sur-Seine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Vitry-sur-Seine</wicri:regionArea><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion></affiliation></author><author><name sortKey="Chevalier, Soazig" sort="Chevalier, Soazig" uniqKey="Chevalier S" first="Soazig" last="Chevalier">Soazig Chevalier</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi, Vitry-sur-Seine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Vitry-sur-Seine</wicri:regionArea><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion></affiliation></author><author><name sortKey="Allegra, Carmen J" sort="Allegra, Carmen J" uniqKey="Allegra C" first="Carmen J" last="Allegra">Carmen J. Allegra</name><affiliation wicri:level="1"><nlm:affiliation>University of Florida, Gainesville, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Florida, Gainesville</wicri:regionArea><wicri:noRegion>Gainesville</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24140268</idno><idno type="pmid">24140268</idno><idno type="doi">10.1016/j.ejca.2013.09.013</idno><idno type="wicri:Area/PubMed/Corpus">003A09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A09</idno><idno type="wicri:Area/PubMed/Curation">003885</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003885</idno><idno type="wicri:Area/PubMed/Checkpoint">003885</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003885</idno><idno type="wicri:Area/Ncbi/Merge">001527</idno><idno type="wicri:Area/Ncbi/Curation">001527</idno><idno type="wicri:Area/Ncbi/Checkpoint">001527</idno><idno type="wicri:Area/Main/Merge">003C78</idno><idno type="wicri:Area/Main/Curation">003C28</idno><idno type="wicri:Area/Main/Exploration">003C28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.</title><author><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name><affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: jtabernero@vhio.net.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals Leuven and KU Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospitals Leuven and KU Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Lakom, Radek" sort="Lakom, Radek" uniqKey="Lakom R" first="Radek" last="Lakom">Radek Lakom</name><affiliation wicri:level="3"><nlm:affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Masaryk Memorial Cancer Institute, Brno</wicri:regionArea><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation></author><author><name sortKey="Prausova, Jana" sort="Prausova, Jana" uniqKey="Prausova J" first="Jana" last="Prausová">Jana Prausová</name><affiliation wicri:level="3"><nlm:affiliation>Fakultni nemocnice v Motole, Praha, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Fakultni nemocnice v Motole, Praha</wicri:regionArea><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation></author><author><name sortKey="Ruff, Paul" sort="Ruff, Paul" uniqKey="Ruff P" first="Paul" last="Ruff">Paul Ruff</name><affiliation wicri:level="1"><nlm:affiliation>University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>University of Witwatersrand Faculty of Health Sciences, Johannesburg</wicri:regionArea><wicri:noRegion>Johannesburg</wicri:noRegion></affiliation></author><author><name sortKey="Van Hazel, Guy A" sort="Van Hazel, Guy A" uniqKey="Van Hazel G" first="Guy A" last="Van Hazel">Guy A. Van Hazel</name><affiliation wicri:level="1"><nlm:affiliation>University of Western Australia, Western Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Western Australia, Western Australia</wicri:regionArea><wicri:noRegion>Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Moiseyenko, Vladimir M" sort="Moiseyenko, Vladimir M" uniqKey="Moiseyenko V" first="Vladimir M" last="Moiseyenko">Vladimir M. Moiseyenko</name><affiliation wicri:level="1"><nlm:affiliation>Oncology Research Institute Na.NN.Petrov, St-Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Oncology Research Institute Na.NN.Petrov, St-Petersburg</wicri:regionArea><wicri:noRegion>St-Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Ferry, David R" sort="Ferry, David R" uniqKey="Ferry D" first="David R" last="Ferry">David R. Ferry</name><affiliation wicri:level="1"><nlm:affiliation>Russells Hall Hospital, Dudley, West Midlands, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Russells Hall Hospital, Dudley, West Midlands</wicri:regionArea><wicri:noRegion>West Midlands</wicri:noRegion></affiliation></author><author><name sortKey="Mckendrick, Joseph J" sort="Mckendrick, Joseph J" uniqKey="Mckendrick J" first="Joseph J" last="Mckendrick">Joseph J. Mckendrick</name><affiliation wicri:level="1"><nlm:affiliation>Monash University, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash University, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Soussan Lazard, Karen" sort="Soussan Lazard, Karen" uniqKey="Soussan Lazard K" first="Karen" last="Soussan-Lazard">Karen Soussan-Lazard</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi, Vitry-sur-Seine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Vitry-sur-Seine</wicri:regionArea><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion></affiliation></author><author><name sortKey="Chevalier, Soazig" sort="Chevalier, Soazig" uniqKey="Chevalier S" first="Soazig" last="Chevalier">Soazig Chevalier</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi, Vitry-sur-Seine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Vitry-sur-Seine</wicri:regionArea><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion></affiliation></author><author><name sortKey="Allegra, Carmen J" sort="Allegra, Carmen J" uniqKey="Allegra C" first="Carmen J" last="Allegra">Carmen J. Allegra</name><affiliation wicri:level="1"><nlm:affiliation>University of Florida, Gainesville, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Florida, Gainesville</wicri:regionArea><wicri:noRegion>Gainesville</wicri:noRegion></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bevacizumab</term><term>Camptothecin (administration & dosage)</term><term>Camptothecin (adverse effects)</term><term>Camptothecin (analogs & derivatives)</term><term>Colorectal Neoplasms (drug therapy)</term><term>Colorectal Neoplasms (pathology)</term><term>Diarrhea (chemically induced)</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Fatigue (chemically induced)</term><term>Fluorouracil (administration & dosage)</term><term>Fluorouracil (adverse effects)</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Leucovorin (administration & dosage)</term><term>Leucovorin (adverse effects)</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Neutropenia (chemically induced)</term><term>Prospective Studies</term><term>Receptors, Vascular Endothelial Growth Factor (administration & dosage)</term><term>Receptors, Vascular Endothelial Growth Factor (adverse effects)</term><term>Recombinant Fusion Proteins (administration & dosage)</term><term>Recombinant Fusion Proteins (adverse effects)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Bévacizumab</term><term>Calendrier d'administration des médicaments</term><term>Camptothécine (administration et posologie)</term><term>Camptothécine (analogues et dérivés)</term><term>Camptothécine (effets indésirables)</term><term>Diarrhée ()</term><term>Estimation de Kaplan-Meier</term><term>Fatigue ()</term><term>Fluorouracil (administration et posologie)</term><term>Fluorouracil (effets indésirables)</term><term>Humains</term><term>Leucovorine (administration et posologie)</term><term>Leucovorine (effets indésirables)</term><term>Métastase tumorale</term><term>Méthode en double aveugle</term><term>Neutropénie ()</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Protéines de fusion recombinantes (administration et posologie)</term><term>Protéines de fusion recombinantes (effets indésirables)</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire (administration et posologie)</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire (effets indésirables)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Tumeurs colorectales (anatomopathologie)</term><term>Tumeurs colorectales (traitement médicamenteux)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Camptothecin</term><term>Fluorouracil</term><term>Leucovorin</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Camptothécine</term><term>Fluorouracil</term><term>Leucovorine</term><term>Protéines de fusion recombinantes</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Camptothecin</term><term>Fluorouracil</term><term>Leucovorin</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Camptothecin</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Camptothécine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs colorectales</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Diarrhea</term><term>Fatigue</term><term>Neutropenia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Camptothécine</term><term>Fluorouracil</term><term>Leucovorine</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Protéines de fusion recombinantes</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs colorectales</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Bevacizumab</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Prospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Bévacizumab</term><term>Calendrier d'administration des médicaments</term><term>Diarrhée</term><term>Estimation de Kaplan-Meier</term><term>Fatigue</term><term>Humains</term><term>Métastase tumorale</term><term>Méthode en double aveugle</term><term>Neutropénie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the present analysis, outcomes were evaluated in prespecified subgroups to assess the consistency of the treatment effect.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Australie</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Royaume-Uni</li><li>Russie</li><li>République tchèque</li><li>États-Unis</li></country><region><li>Bohême centrale</li><li>Catalogne</li><li>Moravie</li></region><settlement><li>Barcelone</li><li>Brno</li><li>Prague</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name></region></country><country name="Belgique"><noRegion><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name></noRegion></country><country name="République tchèque"><region name="Moravie"><name sortKey="Lakom, Radek" sort="Lakom, Radek" uniqKey="Lakom R" first="Radek" last="Lakom">Radek Lakom</name></region><name sortKey="Prausova, Jana" sort="Prausova, Jana" uniqKey="Prausova J" first="Jana" last="Prausová">Jana Prausová</name></country><country name="Afrique du Sud"><noRegion><name sortKey="Ruff, Paul" sort="Ruff, Paul" uniqKey="Ruff P" first="Paul" last="Ruff">Paul Ruff</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Van Hazel, Guy A" sort="Van Hazel, Guy A" uniqKey="Van Hazel G" first="Guy A" last="Van Hazel">Guy A. Van Hazel</name></noRegion><name sortKey="Mckendrick, Joseph J" sort="Mckendrick, Joseph J" uniqKey="Mckendrick J" first="Joseph J" last="Mckendrick">Joseph J. Mckendrick</name></country><country name="Russie"><noRegion><name sortKey="Moiseyenko, Vladimir M" sort="Moiseyenko, Vladimir M" uniqKey="Moiseyenko V" first="Vladimir M" last="Moiseyenko">Vladimir M. Moiseyenko</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Ferry, David R" sort="Ferry, David R" uniqKey="Ferry D" first="David R" last="Ferry">David R. Ferry</name></noRegion></country><country name="France"><noRegion><name sortKey="Soussan Lazard, Karen" sort="Soussan Lazard, Karen" uniqKey="Soussan Lazard K" first="Karen" last="Soussan-Lazard">Karen Soussan-Lazard</name></noRegion><name sortKey="Chevalier, Soazig" sort="Chevalier, Soazig" uniqKey="Chevalier S" first="Soazig" last="Chevalier">Soazig Chevalier</name></country><country name="États-Unis"><noRegion><name sortKey="Allegra, Carmen J" sort="Allegra, Carmen J" uniqKey="Allegra C" first="Carmen J" last="Allegra">Carmen J. Allegra</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24140268
|texte= Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24140268" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |